JWM
CPRX

JPL Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

JPL Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$124 Buy
+5
New +$119 ﹤0.01% 1451
2025
Q4 		– Sell
-5
Closed -$99 – 330
2025
Q3 		$99 Buy
+5
New +$103 ﹤0.01% 1168

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JPL Wealth Management's CPRX Position: Q1 2026 in Review

JPL Wealth Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 5 shares worth $124. The stake represents ﹤0.01% of the portfolio and ranks #1451 among its holdings. This is a return to the name: JPL Wealth Management previously reported a position in CPRX as recently as Q3 2025.

JPL Wealth Management first reported a position in CPRX in Q3 2025 and has held it in 2 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • JPL Wealth Management held 5 shares of Catalyst Pharmaceutical worth $124 as of Q1 2026.
  • Catalyst Pharmaceutical was a new JPL Wealth Management position in Q1 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of JPL Wealth Management's portfolio in Q1 2026, its #1451 holding.
  • JPL Wealth Management first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 2 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on JPL Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.